MoonLake Immunotherapeutics
MLTX · NASDAQ
Company research
MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biopharmaceutical company headquartered in Zug, Switzerland, focused on developing next-level therapies for inflammatory skin and joint diseases leveraging proprietary Nanobody® technology. The company's lead and sole pipeline candidate, Sonelokimab (SLK), is a novel tri-specific Nanobody that simultaneously inhibits IL-17A and IL-17F dimers, enabling enhanced penetration into deep skin and joint tissues to address inflammation at its source. Sonelokimab is currently being evaluated across multiple Phase 2 and Phase 3 clinical trials targeting conditions with significant unmet medical need, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. Founded in 2021 and led by co-founder and CEO Jorge Santos da Silva, MoonLake — which originally in-licensed Sonelokimab from Merck KGaA — has a market capitalization of approximately USD 1.7 billion and approximately 130 employees as it advances toward potential commercialization in dermatology and rheumatology.
Research reports
Detailed due diligence framing MoonLake as a single‑asset, high‑risk/high‑reward story, with a “Cautiously Bullish” stance, a 40.00 target price, and rNPV-based valuation built on HS and PsA peak sales assumptions. It highlights best‑in‑class long‑term sonelokimab data and robust IP/manufacturing moat as the bull case while stressing binary BLA risk, safety labeling, commercialization challenges without a partner, and dilution risk as key downside factors.
Yahoo Finance (analysis Article) · June 25, 2026How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On OfferingThis note reviews strong Week 52 VELA efficacy and safety data plus a 200 million follow‑on equity raise, arguing these moves de‑risk the clinical and funding path ahead of the planned HS BLA while boosting liquidity. However, based on its valuation work the author concludes MLTX may be overvalued at current levels, emphasizing regulatory, execution, and dilution risks and suggesting a cautious stance despite positive clinical momentum.
BiostockInfo · March 30, 2026MoonLake (MLTX) Thesis Update: The Data Is SpeakingA comprehensive thesis update that revisits MLTX after the 2025 VELA sell‑off, arguing Week 40 HS data, axSpA S‑OLARIS results, and FDA clarity now support a best‑in‑class sonelokimab profile across HS, PsA, axSpA, PPP, and psoriasis. It maintains a “cautiously positive” but clearly bullish view with a base‑case 10 billion‑plus valuation by 2028 and lays out detailed bull and bear cases around 52‑week durability, IZAR PsA readouts, competitive dynamics versus Bimzelx/Cosentyx, funding runway, Hercules debt tranches, regulatory risks, and potential strategic takeout scenarios.
Evranic (Substack) · February 18, 2026If “All Gaps Get Filled”, MoonLake Immunotherapeutics Looks on the Verge of a Major BreakoutThis report combines technical and fundamental analysis, arguing the risk‑reward skews bullish after a 90% post‑trial drop, given FDA guidance that no additional HS trials are required for a BLA and Fast Track status in palmoplantar pustulosis. It builds a speculative long thesis around a potential chart “gap fill” towards 30–40, upcoming BLA submission, and buyout chatter (e.g., rumored Merck interest), while acknowledging that the idea is higher‑risk and driven by both sentiment and catalysts.